Search

The article discusses the various cases of inflammatory bowel diseases (IBD) based on medical research studies. Topics discussed include providing the best treatment procedures for anal fistula, treatment options for severe cases of Endometriosis and colectomy, along with a brief about rectal prolapse surgery.

Aim Duodenal adenomas occur in about 90% of patients with familial adenomatous polyposis (FAP) and are the second cause of death of patients who have had a prophylactic proctocolectomy. Studies suggest that biliary acids have a role in the development of duodenal adenomas. The aim of this study was to evaluate the impact of ursodesoxycholic acid (UDCA) on duodenal adenoma formation in patients with FAP. Method A randomized, double-blinded, placebo-controlled study was carried out of 71 patients (20-65 years) who already had a restorative proctocolectomy. Subjects received either 10 mg/kg of UDCA orally per day or a placebo tablet for 24 months. The Spigelman severity score was determined after duodenal axial and lateral view endoscopy at 12 and 24 months. Results At 2 years 55 patients had completed the entire period of treatment. At the end of the follow-up period, nine (25%) patients in the UDCA group and seven (20%) in the placebo group had a decrease in the Spigelman score ( P = 0.6142). Patients receiving UDCA had no side-effects (0%) compared with four (14%) in the placebo group ( P = 0.0392). Conclusion UDCA had no effect on the development of duodenal adenomas in FAP patients (NCT: 00134758). [ABSTRACT FROM AUTHOR]